“Screening Without AI May Soon Be Unthinkable”… The Shifting Standard in Europe
A monumental change is on the horizon for the German healthcare market. As early as 2026, lung cancer screening using Low-Dose Computed Tomography (LDCT) is expected to be introduced as a statutory health insurance benefit.
This anticipated decision by the Federal Joint Committee (G-BA) would represent a national resolve to shift the axis of health policy from ‘treatment’ to ‘prevention’ and to lower the mortality rate of lung cancer, which claims tens of thousands of lives annually.
However, the ‘real news’ industry stakeholders must focus on is this: the utilization of AI-based Computer-Aided Detection software is expected to become mandatory.
Not a Recommendation, but a Mandate... What Changed?
In past lung cancer screening pilot projects, AI software was merely an ‘optional tool’ to assist physicians. In the early stages of adopting new technology, it is common to use incentives such as ‘recommendations’ or ‘add-on reimbursement fees.’
However, Germany is moving toward specifying the use of AI solutions as a mandatory prerequisite alongside the anticipated reimbursement decision. The rationale is clear. National-level lung cancer screening is fundamentally different from individual patient care. It involves analyzing massive volumes of CT scans from hundreds of thousands of high-risk individuals daily. In this process, structural challenges arise that human capability alone cannot easily overcome:
- Inter-reader Variability: The limitation that reading results may vary depending on the radiologist’s proficiency or daily condition.
- Reproducibility: The quality control issue requiring that the same nodule yields consistent measurements regardless of who measures it or when.
- Workflow Bottlenecks: The realistic constraint of handling exploding screening demand with a limited workforce of specialized radiologists.
Germany appears set to determine that AI is the most viable alternative capable of solving these challenges while simultaneously guaranteeing both accuracy and efficiency.
Germany’s Emerging Message: “AI Is Now Infrastructure”
The direction Germany is taking carries profound significance. It would be among the first instances established, as a Standard of Care, that LDCT hardware alone is insufficient and must be accompanied by software infrastructure for analysis and management. This shift aligns with the critical questions raised by the
ZORALCS study we discussed previously.
AI is no longer being viewed as just an assistant; its status is being elevated to ‘Essential Infrastructure’ for the stable operation of screening within a real-world healthcare system. In other words, to sustain the effectiveness of lung cancer screening, a systemic foundation capable of consistently applying standardized reading criteria is considered essential. Germany’s anticipated decision would be a case of explicitly reflecting this requirement in its regulations.
Post-Reimbursement: What Solutions Will Germany Seek?
So, once full-scale reimbursement begins, what kind of software will the German medical field choose? The criteria will likely not stop at “Does the algorithm perform better?” It will inevitably demand solutions that understand the German medical environment and clinical workflow, backed by verified data and operational experience.
Claiming “Our algorithm has a higher AUC” is no longer expected to be enough. The market appears to be moving past the era of performance competition; ‘National Screening Readiness’ is emerging as the new standard of judgment.
FDA or CE certification is now merely a baseline requirement. Going forward, real-world experience in operating actual national screening projects and the adaptability to guidelines accumulated during that process are poised to become the key criteria determining market success.
The Start of a New Standard, and HANSE
Coreline Soft already holds deep ties with Germany. The company participated as the
main solution provider for the HANSE Project, which laid the groundwork for Germany’s anticipated lung cancer screening reimbursement. In this large-scale study led by Hannover Medical School (MHH), Coreline’s AVIEW was selected as the sole solution, proving its stability and technical capability in the actual German medical field for over two years.
- Local Verification Complete: Possesses workflow experience optimized for German medical staff and systems.
- Global References: Executed screening projects not only in Germany but also in major European nations including Italy and France.
Germany’s anticipated reimbursement for lung cancer screening is poised to be the signal flare opening the gates of the European medical AI market. And those gates are expected to open only to prepared companies holding the key of ‘Mandatory AI Utilization.
A solution verified by Germany and chosen by Europe—please watch the future of lung cancer screening that
Coreline Soft will build.
[Editor's Note] As a standard-setter in Medical AI, Coreline Soft leverages AI technology ethically and efficiently in its content creation process. This article was drafted with the assistance of AI analysis and has been reviewed and verified by internal experts.
List
